Latest news with #pharma
Yahoo
12 hours ago
- Business
- Yahoo
Kaida BioPharma Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand FORT LAUDERDALE, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Kaida BioPharma ('Kaida' or the 'Company'), an early-stage pharma company dedicated to advancing targeted anti-cancer therapies to address hormone-driven cancers affecting women, today announced Stella Vnook, PhD, Co-Founder of Kaida, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. For the event, Dr. Vnook dove deeper into her dedication to the Company, how she got to where she is today and provided insight into why she is so passionate about the Company's program in development. The on-demand video webcast is now available on About Kaida BioPharmaKaida BioPharma was founded on the research principles and clinical evidence of the therapeutic benefit of blocking the binding of prolactin (PRL), a multifunctional hormone, to its receptor (PRLR), given their roles as growth factors in tumor growth and proliferation. The Company's lead product candidate KAD101 is a growth hormone antagonist designed to selective and effectively block the tumoral PRL/PRLR axis which has been shown to induce programmed cell death (autophagy) in gynecologic tumors. The Company is collaborating closely with Dr. John Langenheim, professor at Thomas Jefferson University, and Dr. Anil Sood, professor and vice chair for translational research in the departments of gynecologic oncology and cancer biology at MD Anderson Cancer Center, who have both published extensive research on prolactin and its role as a growth factor in tumor growth and progression and the potential therapeutic benefit of KAD101. Kaida is dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. The Company's mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference. For more information, please visit ContactJenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775E: kaida@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
AstraZeneca PLC (AZN)'s Datroway Wins FDA Nod for Lung Cancer Breakthrough
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. AstraZeneca PLC stands fifth on our list among the most undervalued stocks. AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical company headquartered in Cambridge, UK, operates in over 130 countries with more than 80,000 employees. Formed in 1999 through the merger of Astra AB and Zeneca Group, the company is a leader in oncology, rare diseases, and biopharmaceuticals, with R&D hubs in Cambridge (UK), Gothenburg (Sweden), and Gaithersburg (US). A major recent milestone for the company is the U.S. FDA approval of Datroway (datopotamab deruxtecan) for patients with EGFR-mutated, previously treated non-small cell lung cancer (NSCLC). Datroway is the first TROP2-directed antibody-drug conjugate approved for this indication and offers improved progression-free and overall survival compared to chemotherapy, based on results from the Phase III TROPION-Lung01 trial. The drug was co-developed with Daiichi Sankyo, showcasing AstraZeneca PLC (NASDAQ:AZN)'s focus on collaborative innovation. This approval strengthens the company's extensive oncology portfolio, which includes Tagrisso, Imfinzi, and Enhertu, and supports its leadership in targeted cancer therapies. Beyond lung cancer, AZN is advancing treatments across other cancers. The SERENA-6 trial showed positive Phase III results for camizestrant, an oral SERD for HR-positive breast cancer, while the MATTERHORN trial reported promising data for Imfinzi in early-stage gastric and gastroesophageal junction cancers. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) continues to drive global oncology research, regularly presenting plenary data at leading medical conferences like ASCO, reflecting its position at the forefront of cancer innovation. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Johnson & Johnson (JNJ): I Counted 15 Separate Surprises,' Says Jim Cramer
We recently published . Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ)'s shares are up by 5% since its latest earnings report, which saw it post $23.7 billion in sales to beat analyst estimates of $22.8 billion. Crucially, the shares were helped by Johnson & Johnson (NYSE:JNJ)'s midpoint annual revenue guidance, which the firm raised by $2 billion, and by its midpoint full year EPS of $10.85, which marked a 25-cent jump. Cramer was impressed by Johnson & Johnson (NYSE:JNJ)'s results and shared that the firm surprised on 15 different metrics: 'And then yesterday, unheard and unsung, but we're going to change that. Johnson & Johnson. Johnson & Johnson delivered a quarter, I counted 15 separate surprises. . .15 different things. That they beat on. All sorts of different metrics.' A smiling baby with an array of baby care products in the foreground. Previously, he discussed Johnson & Johnson (NYSE:JNJ)'s prospects ahead of the earnings release: 'Johnson & Johnson kicks off pharma earnings season on Wednesday, and I think once again, the company will not be rewarded for its consistency or its originality because there's still the sort of the talc lawsuits hanging over it. I don't mind JNJ fighting the plaintiff's part, but it sure puts a damper on the stock.' While we acknowledge the potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 days ago
- Business
- Yahoo
CPHI & PMEC Shenzhen 2025: Unlocking New Opportunities in Asia and the Greater Bay Area
SHANGHAI, July 21, 2025 /PRNewswire/ -- CPHI & PMEC China 2025 concluded in June with a record-breaking 109,056 attendees, underscoring strong demand within China's thriving pharma industry. Building on this success, CPHI & PMEC Shenzhen 2025 will take place from 1–3 September 2025 at Shenzhen Convention & Exhibition Center (SZCEC), addressing the growing demand for access to South China's key pharma markets. As a key gateway to the Guangdong-Hong Kong-Macau Greater Bay Area, Shenzhen is positioned to drive pharma innovation. The region's health industry GDP is projected to surpass 2 trillion CNY by 2028 and reach 2.5 trillion to 3 trillion CNY by 2030, offering unparalleled opportunities for growth and collaboration. CPHI & PMEC Shenzhen is set to achieve remarkable growth in 2025, doubling its size to 30,000 sqm of show floor and featuring over 600 selected exhibiting companies from various sectors of the pharmaceutical industry, including pharma ingredients, excipients, biotech, contract services, pharma machinery, packaging machinery, packaging materials and more. The event will expand product zones for natural supply, finished dosage, clean technology and laboratory instruments. A new 'Beauty & Cosmetics Supply Chain Zone' will showcase products and foster collaboration in this rapidly growing sector. During the exhibition, over 20 high-level forums will bring together regulatory authorities, academic experts, and corporate leaders to deliver in-depth analysis of policy shifts, technological breakthroughs, and emerging market dynamics. Key topics include new drug R&D, API process optimisation, CXO collaborations, emerging markets strategy, nutrition and health food development, natural ingredients and functional food development, injectable medical aesthetics innovation, pharma packaging solutions, pharma manufacturing 4.0, pharmaceutical engineering and more. To forge strategic partnerships, exclusive Hosted Buyer Matchmaking and Plant visit will be organized. These initiatives will facilitate meaningful interactions between suppliers and international buyers with specific purchasing demand. With its strategic location and curated focus, CPHI & PMEC Shenzhen 2025 is set to redefine pharma innovation in South China. The event offers unparalleled opportunities for networking, knowledge exchange, and collaboration, empowering attendees to unlock new growth horizons across Asia's thriving pharmaceutical sector. Register as a visitor before 1 August to enjoy complimentary VIP benefits: For more information, please visit: View original content to download multimedia: SOURCE CPHI & PMEC Shenzhen
Yahoo
3 days ago
- Business
- Yahoo
Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector
Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. The company rose to prominence during the COVID-19 pandemic thanks to its antiviral drug remdesivir, one of the earliest approved treatments for the virus. However, despite its scientific breakthroughs and commercial achievements, Gilead has lagged behind the broader market over the past ten years, as investors remain cautious about its growth prospects and ability to deliver on its pipeline. That said, Gilead Sciences, Inc. (NASDAQ:GILD)'s cash position remained stable, which makes it one of the best dividend stocks in the pharma sector. In the first quarter of 2025, the company generated $1.8 billion in operating cash flow and had $7.9 billion available in cash and cash equivalents. During the quarter, it also returned $1 billion to investors through dividends. Gilead Sciences, Inc. (NASDAQ:GILD) currently offers a quarterly dividend of $0.79 per share and has a dividend yield of 2.90%, as of July 17. The company has raised its payouts every year since 2015. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
